French vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) on Tuesday reported sustained antibody responses five years after a single dose of its chikungunya vaccine, IXCHIQ, with 94% of 221 evaluable participants maintaining neutralising antibody levels above the seroresponse threshold.
The five-year results demonstrated comparable antibody persistence among adults aged 65 and older and those aged 18 to 64, further supporting the vaccine's potential to provide long-term protection following a single vaccination.
The VLA1553-303 trial, supported by the Coalition for Epidemic Preparedness Innovations (CEPI) and the European Union's Horizon Europe programme, will continue monitoring participants for up to ten years to assess long-term immune response durability.
Valneva is also generating real-world evidence through post-marketing initiatives, including Brazil's first large-scale public vaccination campaign using IXCHIQ. Conducted between February and October 2026 by Brazil's Ministry of Health and Instituto Butantan, with Valneva's support, the campaign vaccinated nearly 80,000 adults aged 18 to 59.
The ongoing post-marketing studies are expected to provide further effectiveness and safety data, supporting the assessment of IXCHIQ's public health value.
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Breakthrough T1D and Walgreens Foundation join forces to support the type 1 diabetes community
PAI Pharma acquires Nexus Pharmaceuticals
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Guardant Health expands liquid biopsy test with AI-powered epigenomic applications
Nuvation Bio to present at Jefferies Global Healthcare Conference in London
AstraZeneca acquires biotechnology company Omniose to strengthen vaccine capabilities
Valneva reports 94% antibody persistence five years after single-dose chikungunya vaccination
bioMérieux secures FDA clearance and IVDR CE marking for VITEK PRO diagnostic platform
Energenesis Biomedical presents ENERGI-based approach to space anaemia at TASTI 2026
Janux reports positive Phase 1 data for JANX011, plans autoimmune trials in 2027
Illumina expands MRD research portfolio with ultrasensitive sequencing technology